Management of severe bacterial infections

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 4, 2005, Pages 593-600

  Esposito, Silvano ^a   Leone, Sebastiano ^a   Noviello, Silvana ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antibiotic therapy; Appropriate and inappropriate therapy; Infectious disease specialist; Severe infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; MEROPENEM; METICILLIN; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CANDIDA; CARDIOVASCULAR DISEASE; COMORBIDITY; CONSULTATION; COOPERATION; DECISION SUPPORT SYSTEM; DISEASE DURATION; DISEASE SEVERITY; DRUG POTENTIATION; DRUG UTILIZATION; EAR DISEASE; ENTEROCOCCUS; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAND WASHING; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INDIVIDUALIZATION; INTENSIVE CARE UNIT; KIDNEY DISEASE; LAPAROTOMY; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; PATIENT CARE; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; PROTECTIVE CLOTHING; PSEUDOMONAS AERUGINOSA; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SEPSIS; STAPHYLOCOCCUS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 24044447215     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.4.593     Document Type: Review

References (52)

1. Juthani-Mehta M, Quagliarello VJ. Prognostic scoring systems for infectious disease: their applicability to the care of older adults. Clin. Infect. Dis. 38(5), 692-696 (2004).
2. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31(Suppl. 4), 131-138 (2000).
3. Edmond MB, Ober JF, Weinbaum DL et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20(5), 1126-1133 (1995).
4. Husni RN, Goldstein LS, Arroliga AC et al. Risk factors for an outbreak of multi-drug resistant Acinetobacter nosocomial, pneumonia among intubated patients. Chest 115(5), 1378-1382 (1999).
5. Schentag JJ, Hyatt JM, Carr JR et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin. Infect. Dis. 26(5), 1204-1214 (1998).
6. Owens G, Felts JA, Spitznagel EL. ASA physical status classification: a study consistency of ratings. Anesthesiology 49(4), 239-243 (1978).
7. Knaus WA, Draper EA, Wagner EA, Zimmerman JE. APACHE II: a severity of disease classification system. Crit. Care Med. 13(10), 818-829 (1985).
8. B'Erard F, Gandon J. Postoperative wound infections: the influence of ultraviolet irradiation of the operating room and various other factors. Ann. Surg. 160(Suppl. 1), 1-192 (1964).
9. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336(4), 243-250 (1997).
10. Miles EC, Abraira V, Sanchez JC et al. A predictive model for mortality of bloodstream infections: bedside analysis with the Weibull function. J. Clin. Epidemiol. 55(6), 563-572 (2002).
11. Esposito S, Leone S, Noviello S, Ianniello F. Management of severe bacterial infections and role of the infectious disease specialist: results of an interview-based survey. Infez. Med. 12(2), 90-100 (2004).
12. Baughman RP, Tapson V, McIvor A. The diagnosis and treatment challenges in nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 33(2), 131-139 (1999).
13. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society. Am. J. Respir. Crit. Care Med. 153(5), 1711-1725 (1996).
14. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348(16), 1546-1554 (2003).
15. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit. Care Med. 26(12) 2078-2086 (1998).
16. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 365(9453), 63-78 (2005).
17. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr. Opin. Infect. Dis. 17(4), 309-316 (2004).
18. Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur. J. Cancer 38(Suppl. 4), 82-87 (2002).
19. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin. Infect. Dis. 40(Suppl. 4), 240-245 (2005).
20. Farthman EH, Schöffel U. Epidemiology and pathophysiology of intra-abdominal infections (IAI). Infection 26(5), 329-334 (1998).
21. Jansen HH. Postmortem findings in peritonitis. Leber Magen Darm 11(4), 167-173 (1981).
22. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244(5), 379-386 (1998).
23. Luna CM, Vujacich P, Niedeman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111(3), 676-685 (1997).
24. Kollef MH. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am. J. Med. 115(3), 1582-1584 (2003).
25. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156(1), 196-200 (1997).
26. MacArthur RD, Miller M, Albertson T et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis. 38(2), 284-288 (2004).
27. Behrendt G, Schneider S, Brodt HR, Just-Nubling G, Shah PM. Influence of antimicrobial treatment on mortality in septicemia. J. Chemother. 11(3), 179-186 (1999).
28. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5(1), 9-17 (1999).
29. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118(1), 146-155 (2000).
30. National Nosocomial Infections Surveillance (NNIS). System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27(6), 520-532 (1999).
31. McGowan JE. Minimizing antimicrobial resistance: the key role of the infectious diseases physician. Clin. Infect. Dis. 38(7), 939-942 (2004).
32. Kish MA. Guide to development of practice guidelines. Clin. Infect. Dis. 32(6), 851-854 (2001).
33. McNulty CA. Optimising antibiotic prescribing in primary care. Int. J. Antimicrob. Agents 18(4), 329-333 (2001).
34. Tamblyn R, Huang A, Perreault R et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. Can. Med. Assoc. J. 169(6), 549-556 (2003).
35. Mullett CJ, Thomas JG, Smith CL, Sarwari AR, Khakoo RA. Computerized antimicrobial decision support: an offline evaluation of a database-driven empiric antimicrobial guidance program in hospitalized patients with a bloodstream infection. Int. J. Med. Inform. 73(5), 455-460 (2004).
36. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn. Microbiol. Infect. Dis. 38(1), 37-41 (2000).
37. Burgess DS, Nathisuwan S. Cefepime, pipericillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 44(1), 35-41 (2002).
38. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47(9), 2756-2764 (2003).
39. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4(8), 519-527 (2004).
40. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. β-lactam versus β-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst. Rev. 3(CD003038) (2003).
41. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 29(6), 1109-1115 (2001).
42. Trouillet JL, Chastre J, Vuagnat A et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157(2), 531-539 (1998).
43. Rello J, Vidaur L, Sandiumenge A et al. De-escalation therapy in ventilator-associated pneumonia. Crit. Care Med. 32(11), 2183-2190 (2004).
44. Gruson D, Hilbert G, Vargas F et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am. J. Respir. Crit. Care Med. 162(3), 837-843 (2000).
45. Gruson D, Hilbert G, Vargas F et al. Strategy of antibiotic rotation: long-term effect on the incidence and the susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit. Care Med. 31(7), 1908-1914 (2003).
46. Raymond DP, Pelletier SJ, Crabtree TD et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit. Care Med. 29(6), 1101-1108 (2001).
47. Byl B, Clevenbergh P, Jacobs F et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin. Infect. Dis. 29(1), 60-66 (1999).
48. Fowler VG, Sanders LL, Sexton DJ et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious disease specialist: experience with 244 patients. Clin. Infect. Dis. 27(3), 478-486 (1998).
49. Borer A, Gilad J, Meydan N. Impact of regular attendance by infectious disease specialists on the management of hospitalised adults with community-acquired febrile syndromes. Clin. Microbiol. Infect. 10(10), 911-916 (2004).
50. Fluckiger U, Zimmmerli W, Sax H et al. Clinical impact of an infectious disease service on the management of bloodstream infection. Eur. J. Clin. Microbiol. Infect. Dis. 19(7), 493-500 (2000).
51. Lemmen SW, Becker G, Frank U, Daschner FD. Influence of an infectious disease consulting service on quality and costs of antibiotic prescriptions in a university hospital. Scand. J. Infect. Dis. 33(3), 219-221 (2001).
52. Lemmen SW, Hafner H, Kotterik S, Lutticken R, Topper R. Influence of an infectious disease service on antibiotic prescription behaviour and selection of multiresistant pathogens. Infection 28(6), 384-387 (2000).